PL3274366T3 - Chimeryczny receptor antygenowy - Google Patents

Chimeryczny receptor antygenowy

Info

Publication number: PL3274366T3
Authority: PL; Poland
Prior art keywords: antigen receptor; chimeric antigen; chimeric; receptor; antigen
Prior art date: 2015-03-23

Application number

PL16712424T

Other languages

English (en)

Inventor

Martin PULÉ

Shaun CORDOBA

Original Assignee

Ucl Business Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-03-23

Filing date

2016-03-22

Publication date

2020-06-15

2016-03-22 Application filed by Ucl Business Ltd filed Critical Ucl Business Ltd

2020-06-15 Publication of PL3274366T3 publication Critical patent/PL3274366T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4244—Enzymes
- A61K40/4251—Kinases, e.g. Raf or Src
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/23—On/off switch
- A61K2239/24—Dimerizable CARs; CARs with adapter
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Medicinal Chemistry (AREA)
Cell Biology (AREA)
Biochemistry (AREA)
Hematology (AREA)
Pharmacology & Pharmacy (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Oncology (AREA)
Virology (AREA)
Developmental Biology & Embryology (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

PL16712424T 2015-03-23 2016-03-22 Chimeryczny receptor antygenowy PL3274366T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB1504840.8A GB201504840D0 (en)	2015-03-23	2015-03-23	Chimeric antigen receptor
EP16712424.7A EP3274366B8 (en)	2015-03-23	2016-03-22	Chimeric antigen receptor
PCT/GB2016/050795 WO2016151315A1 (en)	2015-03-23	2016-03-22	Chimeric antigen receptor

Publications (1)

Publication Number	Publication Date
PL3274366T3 true PL3274366T3 (pl)	2020-06-15

Family

ID=53052211

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL16712424T PL3274366T3 (pl)	2015-03-23	2016-03-22	Chimeryczny receptor antygenowy

Country Status (21)

Country	Link
US (1)	US11058722B2 (pl)
EP (1)	EP3274366B8 (pl)
JP (3)	JP6675417B2 (pl)
KR (1)	KR102174280B1 (pl)
CN (1)	CN107406518B (pl)
AU (1)	AU2016238583B2 (pl)
BR (1)	BR112017018252A2 (pl)
CA (1)	CA2978852C (pl)
CL (1)	CL2017002413A1 (pl)
DK (1)	DK3274366T3 (pl)
ES (1)	ES2773527T3 (pl)
GB (1)	GB201504840D0 (pl)
HU (1)	HUE047929T2 (pl)
IL (1)	IL254254B (pl)
MX (1)	MX371384B (pl)
PL (1)	PL3274366T3 (pl)
PT (1)	PT3274366T (pl)
RU (1)	RU2752880C2 (pl)
SG (1)	SG11201706940QA (pl)
WO (1)	WO2016151315A1 (pl)
ZA (1)	ZA201705682B (pl)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2014117121A1 (en)	2013-01-28	2014-07-31	St. Jude Children's Research Hospital, Inc.	A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
US11385233B2 (en)	2015-03-05	2022-07-12	Autolus Limited	Methods of depleting malignant T-cells
US11982672B2 (en)	2014-03-05	2024-05-14	Autolus Limited	Methods
GB201403972D0 (en)	2014-03-06	2014-04-23	Ucl Business Plc	Chimeric antigen receptor
GB201405845D0 (en)	2014-04-01	2014-05-14	Ucl Business Plc	Signalling system
SG11201609118RA (en)	2014-05-15	2016-11-29	Univ Singapore	Modified natural killer cells and uses thereof
GB201415347D0 (en)	2014-08-29	2014-10-15	Ucl Business Plc	Signalling system
GB201501936D0 (en) *	2015-02-05	2015-03-25	Ucl Business Plc	Signalling system
CA2986254A1 (en)	2015-05-18	2016-11-24	TCR2 Therapeutics Inc.	Compositions and methods for tcr reprogramming using fusion proteins
WO2017180587A2 (en)	2016-04-11	2017-10-19	Obsidian Therapeutics, Inc.	Regulated biocircuit systems
GB201610512D0 (en)	2016-06-16	2016-08-03	Autolus Ltd	Chimeric antigen receptor
EP3494138A1 (en)	2016-08-02	2019-06-12	TCR2 Therapeutics Inc.	Compositions and methods for tcr reprogramming using fusion proteins
JP7217970B2 (ja)	2016-10-07	2023-02-06	ティーシーアール２セラピューティクスインク．	融合タンパク質を用いてｔ細胞受容体をリプログラミングするための組成物及び方法
CN110177803A (zh)	2016-11-22	2019-08-27	T细胞受体治疗公司	用于使用融合蛋白进行tcr重新编程的组合物和方法
CA3056439A1 (en)	2017-03-27	2018-10-04	National University Of Singapore	Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
WO2018182511A1 (en)	2017-03-27	2018-10-04	National University Of Singapore	Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
CA3056942A1 (en) *	2017-03-29	2018-10-04	Sunnybrook Research Institute	Engineered t-cell modulating molecules and methods of using same
JP7356354B2 (ja)	2017-05-12	2023-10-04	クリスパーセラピューティクスアクチェンゲゼルシャフト	細胞の操作のための材料及び方法並びに免疫腫瘍学におけるその使用
US11166985B2 (en)	2017-05-12	2021-11-09	Crispr Therapeutics Ag	Materials and methods for engineering cells and uses thereof in immuno-oncology
WO2019025800A1 (en) *	2017-08-02	2019-02-07	Autolus Limited	CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE
EP3704150A1 (en)	2017-11-01	2020-09-09	F. Hoffmann-La Roche AG	The compbody - a multivalent target binder
GB201801831D0 (en) *	2018-02-05	2018-03-21	Autolus Ltd	Chimeric receptor
JP7360174B2 (ja)	2018-02-09	2023-10-12	ナショナルユニヴァーシティーオブシンガポール	ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
US12441787B2 (en)	2018-04-02	2025-10-14	National University Of Singapore	Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
CN112105420A (zh)	2018-05-11	2020-12-18	克里斯珀医疗股份公司	用于治疗癌症的方法和组合物
JP7335272B2 (ja)	2018-05-15	2023-08-29	オートラスリミテッド	キメラ抗原受容体
GB201807870D0 (en)	2018-05-15	2018-06-27	Autolus Ltd	A CD79-specific chimeric antigen receptor
EP3836944A4 (en) *	2018-08-16	2022-05-11	Memorial Sloan Kettering Cancer Center	LEUCINE ZIPPER BASED COMPOSITIONS AND METHODS OF USE
CN109265550B (zh) *	2018-09-25	2020-09-15	华东师范大学	Bcma抗体、嵌合抗原受体和药物
PL3856775T3 (pl)	2018-09-27	2025-06-09	Autolus Limited	Chimeryczny receptor antygenowy
KR20210075117A (ko) *	2018-10-05	2021-06-22	세인트 안나 킨더크렙스포르슝	키메라 항원 수용체(car) 그룹
CN113286608A (zh) *	2018-10-05	2021-08-20	圣安娜儿童癌症研究中心	嵌合抗原受体（car）组
GB201817822D0 (en)	2018-10-31	2018-12-19	Autolus Ltd	Binding domain
WO2020172643A2 (en) *	2019-02-21	2020-08-27	Luk John M	Artificial immunosurveillance chimeric antigen receptor (ai-car) and cells expressing the same
CN118546960A (zh)	2019-03-05	2024-08-27	恩卡尔塔公司	Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
SG11202109002XA (en)	2019-03-21	2021-09-29	Regeneron Pharma	Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
PH12021552963A1 (en)	2019-04-30	2022-07-25	Crispr Therapeutics Ag	Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
GB201919017D0 (en)	2019-12-20	2020-02-05	Autolus Ltd	Cell
CN111234033B (zh) *	2020-01-21	2021-05-11	南京北恒生物科技有限公司	多链嵌合抗原受体及其用途
GB202004263D0 (en)	2020-03-24	2020-05-06	Autolus Ltd	Antibody conjugate
GB202005216D0 (en)	2020-04-08	2020-05-20	Autolus Ltd	Cell
GB202006820D0 (en)	2020-05-07	2020-06-24	Autolus Ltd	Cell
GB202017649D0 (en)	2020-11-09	2020-12-23	Autolus Ltd	Polypeptide
WO2022182891A1 (en)	2021-02-25	2022-09-01	Lyell Immunopharma, Inc.	Ror1 targeting chimeric antigen receptor
US20250288672A1 (en) *	2021-03-24	2025-09-18	Raymond Liu	Humanized synthetic notch receptors with augmented transactivation domains and uses thereof
GB202115329D0 (en) *	2021-10-25	2021-12-08	Autolus Ltd	Chimeric cytokine receptor
WO2024019961A1 (en) *	2022-07-18	2024-01-25	Cargo Therapeutics, Inc.	Cd2 recruiting chimeric antigen receptors and fusion proteins
US20250242056A1 (en)	2024-01-26	2025-07-31	Regeneron Pharmaceuticals, Inc.	Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
WO2025160340A2 (en)	2024-01-26	2025-07-31	Regeneron Pharmaceuticals, Inc.	Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025184567A1 (en)	2024-03-01	2025-09-04	Regeneron Pharmaceuticals, Inc.	Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7081443B2 (en)	2002-05-21	2006-07-25	Korea Advanced Institutes Of Science And Technology (Kaist)	Chimeric comp-ang1 molecule
WO2010102518A1 (zh) *	2009-03-13	2010-09-16	北京表源生物技术有限公司	一种融合蛋白多聚体
KR101156085B1 (ko) *	2010-01-29	2012-06-20	국립암센터	４－１ｂｂ리간드（４－１ｂｂｌ）오중합체 및 이의 용도
US10745467B2 (en) *	2010-03-26	2020-08-18	The Trustees Of Dartmouth College	VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
JP6053688B2 (ja) *	2011-10-07	2016-12-27	国立大学法人三重大学	キメラ抗原受容体
KR102437522B1 (ko) *	2012-05-25	2022-08-26	셀렉티스	면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법
EP2893004B1 (en) *	2012-09-04	2018-10-24	Cellectis	Multi-chain chimeric antigen receptor and uses thereof
KR102813881B1 (ko)	2013-02-15	2025-05-28	더 리젠츠 오브 더 유니버시티 오브 캘리포니아	키메라 항원 수용체 및 이의 이용 방법
CN103145849B (zh) *	2013-02-18	2014-06-11	冯振卿	嵌合抗原受体及其用途
KR102483822B1 (ko) *	2013-12-20	2023-01-03	프레드 허친슨 캔서 센터	태그된 키메라 이펙터 분자 및 그의 리셉터
ES2767423T3 (es)	2014-01-13	2020-06-17	Hope City	Receptores de antígenos quiméricos (CARS) con mutaciones en la región del espaciador Fc y métodos para su uso
GB201415347D0 (en)	2014-08-29	2014-10-15	Ucl Business Plc	Signalling system
GB201610512D0 (en)	2016-06-16	2016-08-03	Autolus Ltd	Chimeric antigen receptor

2015
- 2015-03-23 GB GBGB1504840.8A patent/GB201504840D0/en not_active Ceased
2016
- 2016-03-22 WO PCT/GB2016/050795 patent/WO2016151315A1/en not_active Ceased
- 2016-03-22 CN CN201680017370.3A patent/CN107406518B/zh active Active
- 2016-03-22 DK DK16712424.7T patent/DK3274366T3/da active
- 2016-03-22 KR KR1020177030391A patent/KR102174280B1/ko active Active
- 2016-03-22 ES ES16712424T patent/ES2773527T3/es active Active
- 2016-03-22 RU RU2017132978A patent/RU2752880C2/ru active
- 2016-03-22 EP EP16712424.7A patent/EP3274366B8/en active Active
- 2016-03-22 SG SG11201706940QA patent/SG11201706940QA/en unknown
- 2016-03-22 CA CA2978852A patent/CA2978852C/en active Active
- 2016-03-22 HU HUE16712424A patent/HUE047929T2/hu unknown
- 2016-03-22 US US15/560,558 patent/US11058722B2/en active Active
- 2016-03-22 JP JP2017549766A patent/JP6675417B2/ja active Active
- 2016-03-22 MX MX2017010552A patent/MX371384B/es active IP Right Grant
- 2016-03-22 BR BR112017018252-1A patent/BR112017018252A2/pt active Search and Examination
- 2016-03-22 AU AU2016238583A patent/AU2016238583B2/en not_active Ceased
- 2016-03-22 PL PL16712424T patent/PL3274366T3/pl unknown
- 2016-03-22 PT PT167124247T patent/PT3274366T/pt unknown
2017
- 2017-08-21 ZA ZA2017/05682A patent/ZA201705682B/en unknown
- 2017-08-31 IL IL254254A patent/IL254254B/en active IP Right Grant
- 2017-09-25 CL CL2017002413A patent/CL2017002413A1/es unknown
2020
- 2020-01-09 JP JP2020001971A patent/JP2020048588A/ja not_active Withdrawn
2022
- 2022-12-16 JP JP2022201192A patent/JP2023021396A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
EP3274366B1 (en)	2019-12-11
MX2017010552A (es)	2018-03-14
MX371384B (es)	2020-01-28
SG11201706940QA (en)	2017-09-28
EP3274366A1 (en)	2018-01-31
ES2773527T3 (es)	2020-07-13
RU2752880C2 (ru)	2021-08-11
US11058722B2 (en)	2021-07-13
IL254254A0 (en)	2017-10-31
RU2017132978A (ru)	2019-04-08
CA2978852A1 (en)	2016-09-29
RU2017132978A3 (pl)	2019-06-24
JP2018510639A (ja)	2018-04-19
GB201504840D0 (en)	2015-05-06
JP2023021396A (ja)	2023-02-10
AU2016238583B2 (en)	2020-08-13
AU2016238583A1 (en)	2017-09-28
CA2978852C (en)	2021-10-19
CN107406518A (zh)	2017-11-28
HUE047929T2 (hu)	2020-05-28
IL254254B (en)	2021-04-29
JP2020048588A (ja)	2020-04-02
KR102174280B1 (ko)	2020-11-04
PT3274366T (pt)	2020-01-30
US20180050065A1 (en)	2018-02-22
JP6675417B2 (ja)	2020-04-01
CN107406518B (zh)	2022-02-01
EP3274366B8 (en)	2020-02-12
DK3274366T3 (da)	2020-02-10
NZ735267A (en)	2021-04-30
CL2017002413A1 (es)	2018-03-16
KR20180009738A (ko)	2018-01-29
ZA201705682B (en)	2018-12-19
BR112017018252A2 (pt)	2018-04-10
WO2016151315A1 (en)	2016-09-29

Publication	Publication Date	Title
IL280917B (en)	2022-03-01	Cs1 targeted chimeric antigen receptor-modified t cells
PL3274366T3 (pl)	2020-06-15	Chimeryczny receptor antygenowy
IL251030B (en)	2021-07-29	Chimeric antigen receptors
DK3294764T3 (da)	2021-01-25	Kimæriske antigenreceptor sammensætninger
IL257234A (en)	2018-03-29	Chimeric cytokine receptor
CL2016002196A1 (es)	2018-02-16	Receptor antigénico quimérico
PL3230321T3 (pl)	2020-03-31	Chimeryczne receptory antygenowe bcma
GB201503742D0 (en)	2015-04-22	Chimeric antigen receptor
DK3283110T3 (da)	2022-05-23	Antistoffer rettet mod interleukin-36-receptor (il-36r)
PL3230310T3 (pl)	2020-02-28	Chimeryczne receptory antygenowe anty-cd70
GB201617290D0 (en)	2016-11-23	Novel chimeric antigen receptors
GB201607968D0 (en)	2016-06-22	Chimeric antigen receptor
DK3334457T3 (da)	2020-09-21	Humaniserede anti-CCR7-receptorantistoffer
GB201610512D0 (en)	2016-08-03	Chimeric antigen receptor
EP3604344A4 (en)	2021-01-06	CHEMICAL ANTIGENIC RECEPTOR
LT3178931T (lt)	2021-04-12	Anti-orai1 antikūnas
LT3126391T (lt)	2020-02-10	Hpa-1a antikūnai
ITUB20155097A1 (it)	2017-05-05	Anticorpi umanizzati anti-BAG3
GB201519900D0 (en)	2015-12-23	Chimeric antigen receptor
GB201612844D0 (en)	2016-09-07	Chimeric antigen receptor
GB201612533D0 (en)	2016-08-31	Chimeric antigen receptor
GB201604387D0 (en)	2016-04-27	Chimeric antigen receptor
BR112017002234A2 (pt)	2018-07-24	anticorpos anti-pd-l1
GB201409761D0 (en)	2014-07-16	Chimeric antigen receptor
GB201403481D0 (en)	2014-04-16	Chimeric antigen receptor